Loading clinical trials...
Loading clinical trials...
A Randomized Phase II Multicenter Study to Assess the Tolerability and Efficacy of the Addition of Midostaurin to 10-day Decitabine Treatment in Unfit Adult Acute Myeloid Leukemia and High Risk Myelodysplasia Patients
Conditions
Interventions
Decitabine
Midostaurin
Locations
37
Belgium
BE-Antwerpen-ZNASTUIVENBERG
Antwerp, Belgium
BE-Haine-Saint-Paul-JOLIMONT
Haine-Saint-Paul, Belgium
BE-Roeselare-AZDELTA
Roeselare, Belgium
DE-Magdeburg-OVGU
Magdeburg, Germany
NL-Den Bosch-JBZ
's-Hertogenbosch, Netherlands
NL-Amersfoort-MEANDERMC
Amersfoort, Netherlands
Start Date
December 5, 2019
Primary Completion Date
November 15, 2021
Completion Date
November 1, 2026
Last Updated
September 19, 2024
Lead Sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions